Navigation Links
Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
Date:3/24/2009

etic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See www.cepheid.com for more information.

About FIND

FIND, based in Geneva, Switzerland, is a not-for-profit Swiss foundation dedicated to the development of improved diagnostics for poverty-related diseases. FIND is dedicated to the development of tests that will have a measurable impact on TB morbidity and mortality, particularly in high-endemic countries. Since its establishment in 2003, FIND has received endorsement from WHO for three new TB technologies that are currently being rolled out with partners in 16 countries that carry a high burden of MDR TB cases. FIND's mission is to drive the development and implementation of accurate and affordable diagnostic tests that can be used as near as possible to where patients first seek care. At this time, the FIND's disease portfolio includes TB, malaria and human African trypanosomiasis and current donors are the Bill & Melinda Gates Foundation, the European Union, the Government of the Netherlands, UNITAID, Irish Aid and other institutions and private donors. FIND is ISO 9001:2000 and ISO 13485:2003 certified. For more information, please visit: http://www.find
'/>"/>

SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... PORTLAND, Oregon , August 4, 2015 /PRNewswire/ ... published by Allied Market Research, titled, "World Cardiac ... global cardiac biomarker market would generate the revenue ... of 18.9% from 2015 to 2020. Cardiac Troponins ... throughout the forecast period due to high sensitivity ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... diagnostic tests – today announced that Robert A. Gregg, PhD, has joined RPS ... than 30 years of relevant experience and remarkable achievements in the medical device ...
(Date:8/4/2015)... Aug. 4, 2015  Blueprint Medicines (NASDAQ: BPMC ... kinase drugs for genomically defined diseases, today announced that ... a company overview at the 2015 Wedbush PacGrow Healthcare ... EDT. A live webcast of the event ... the Blueprint Medicines website at www.blueprintmedicines.com . An ...
(Date:8/4/2015)... Francisco, CA (PRWEB) , ... August 04, 2015 , ... ... difference by inviting a diverse selection of entrepreneurs from across the United States to ... CEO Jessica Richman is honored to be chosen to be among the attendees. , ...
Breaking Biology Technology:Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2
... Electronic health record systems generally are perceived to have ... more clinics consider moving from paper charts to EHR ... barriers to entry. , ,The evolution of systems for ... robust data security has prompted more hospitals and ...
... - Just six weeks after taking the helm at ... to pursue opportunities in the private sector, the organization announced. ... has served as general counsel to WiCell's parent, the ... high-tech and biotechnology industries. , ,Donley, who joined WARF in ...
... An education research team at the University of Wisconsin-Madison ... to study the impact of digital media on youth ... investment will support 24 national studies of different aspects of ... , ,"What MacArthur is actually trying to do, with this ...
Cached Biology Technology:GE Healthcare launches hybrid electronic record 2Donley resigns as WiCell director 2UW gets $3M to explore educational gaming 2UW gets $3M to explore educational gaming 3
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... a form of breast cancer known as estrogen receptor positive ... the treatment and prevention of recurring breast cancer. Currently, ... dose is prescribed for every patient. New research at ... patient-specific genetic factors, lack of exposure to vitamin D during ...
... DNA code for a complex region of the human genome ... Fraser University, chart new territory in immunity research. , They ... how well they operate and, potentially, what they fight off, ... drugs, treatments and vaccinations are designed to treat whole populations ...
... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... study of seven missense variants of the BRCA1 gene ... to the risk of suffering breast or ovarian cancer. ... PLoS One The classification of these three ...
Cached Biology News:Cold winters freezing out breast cancer treatment 2Scientists find ethnicity linked to antibodies 2Identified as responsible for breast and ovarian hereditary cancer 3 mutations at BRCA1 gene 2
...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Biology Products: